Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jan 24;6(2):133-135.
doi: 10.1016/j.jdcr.2019.11.016. eCollection 2020 Feb.

Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid

William Damsky  1 , Katelyn Singh  1 , Anjela Galan  1   2 , Brett King  1
Affiliations
Case Reports

Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid

William Damsky et al. JAAD Case Rep. .
No abstract available

Keywords: GA, granuloma annulare; ILCS, intralesional corticosteroids; JAK inhibitor; JAK, Janus kinase; Janus kinase; NF-κB, nuclear factor κB; NL, necrobiosis lipoidica; STAT, signal transducer and activator of transcription; necrobiosis lipoidica; p, phosphorylated; tofacitinib.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Clinical and histologic responses of necrobiosis lipoidica to tofacitinib and intralesional corticosteroid. A, Quantification of p-STAT1 and p-STAT3 immunohistochemistry staining in 11 cases of NL from a histologic case series assembled from historical biopsy specimens. Three representative fields were scored for each case, and 7 cases of normal skin were included for comparison (as previously described3,6). *P = .0004, **P = .0027. Data are shown as mean (standard error of the mean). B, Clinical photographs from the patient described in the case report at baseline (left panel), after 6 weeks of tofacitinib (middle panel), and with tofacitinib (9 months' duration) plus concomitant ILCS; the photos in the right panel were taken 8 weeks after ILCS administration. C, Immunohistochemical analysis of biopsy specimens from the patient described in the case report taken at various intervals. Shown are CD68 (macrophage marker), p-STAT1 TYR701 (p-STAT1), p-STAT3 TYR705, and total NF-κB. (NF-κB is only transcriptionally active when present in the nucleus.) IHC, Immunohistochemistry; NF-κB, nuclear factor κB; NL, necrobiosis lipoidica; p, phosphorylated; STAT, signal transducer and activator of transcription.
See this image and copyright information in PMC

References

    1. De Vries L.C.S., Duarte J.M., De Krijger M. A JAK1 Selective kinase inhibitor and tofacitinib affect macrophage activation and function. Inflamm Bowel Dis. 2019;25:647–660. - PubMed
    1. Broglie L., Pommert L., Rao S. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv. 2017;1:1533–1536. - PMC - PubMed
    1. Damsky W., Thakral D., Emeagwali N., Galan A., King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379:2540–2546. - PMC - PubMed
    1. Wei J.J., Kallenbach L.R., Kreider M., Leung T.H., Rosenbach M. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep. 2019;5:360–361. - PMC - PubMed
    1. Rotenberg C., Besnard V., Brillet P.Y., Giraudier S., Nunes H., Valeyre D. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J. 2018;52(6):1–4. - PubMed

Publication types

LinkOut - more resources